The test assesses multiple factors, including single-/multi-nucleotide variants, short insertions and deletions, and microsatellite instability status.
The general LCD is covered for patients with a personal history of melanoma undergoing workups or being evaluated for treatment without metastatic disease.
The firm said that it has secured coverage for about 100 million lives for its targeted NGS liquid biopsy test in the US between Medicare and private payors.